Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595488 · ClinicalTrials.gov registry record · Phase 2
Dupilumab for Aspirin-exacerbated Respiratory Disease
A Phase 2 study of Aspirin-exacerbated Respiratory Disease, sponsored by Rochester General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT03595488: Completed Phase 2 study of Aspirin-exacerbated Respiratory Disease, sponsored by Rochester General Hospital.
NCT03595488 is a Phase 2 study of Aspirin-exacerbated Respiratory Disease that has completed, run by Rochester General Hospital. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03595488, a Phase 2 study of Aspirin-exacerbated Respiratory Disease, has completed, sponsored by Rochester General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.
Primary Outcome
This is a patient-reported outcome score for chronic rhinosinusitis with or without nasal polyposis
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
New York
- Rochester Regional Health - Allergy/Immunology - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 2 |
What the finished NCT03595488 record still lists
NCT03595488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Aspirin-exacerbated Respiratory Disease appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT03595488 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03595488 about?
NCT03595488 is a clinical study titled "Dupilumab for Aspirin-exacerbated Respiratory Disease". Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.
What is the current status of trial NCT03595488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-09-05. Estimated completion is 2019-12-11.
What conditions does trial NCT03595488 study?
This clinical trial studies the following conditions: Aspirin-exacerbated Respiratory Disease.
What interventions are being tested in trial NCT03595488?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03595488?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03595488 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aspirin-exacerbated Respiratory Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03595488's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI